Context Therapeutics Inc. (NASDAQ:CNTX) rose sharply Friday as the company announced data from ONA-XR in early breast cancer. The company said ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer.
ONA-XR significantly increased suppression of tumor cell proliferation. The Phase 0 open-label, single-arm, multicenter ONAWA (SOLTI-1802) trial enrolled 10 patients with ER+/PR+/HER2- negative tumors. While no patients achieved a Complete Cell Cycle Arrest, tumor Ki-67 expression decreased in six patients, remained stable in one patient, and increased in three patients.
Mean percentage decrease of Ki67 for tumors with baseline PR expression ≥90% (N=4) and <90% (N=6) was -25.23% and 2.54%, respectively, indicating a trend towards enhance response for patients with high levels of PR expression at baseline.
The data were presented during the 2021 San Antonio Breast Cancer Symposium. Earlier, Context Therapeutics gains ahead of clinical data for breast cancer candidate.
CEO Martin Lehr said, "ONA-XR is being evaluated in four investigator-sponsored clinical trials in hormone-driven breast, ovarian and endometrial cancers. This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers.
"We look forward to data updates from three other ONA-XR trials in 2022."
CNTX shares began Friday up 63 cents, or 10.3%, to $6.91.
